In a report published Tuesday, Stifel analyst Joel Sendek upgraded the rating on Ariad Pharmaceuticals ARIA from Hold to Buy, and named a $7.00 price target.
In the report, Stifel noted, “We upgrade ARIA from a Hold to a Buy with a price target of $7 based on the overwhelming support that docs at ASH showed for using Iclusig in a salvage population. Our discussions with physicians as ASH were universally positive regarding the risk/benefit for Iclusig and indicating continuing demand for the drug as a 3rd line agent for CML. We forecast resumption of commercial distribution in the US in 2Q14 with a black box warning label indicating increased risk of CV events, in line with the November EMA recommendation of risk factor assessment before treatment and monitoring during treatment.”
Ariad Pharmaceuticals closed on Monday at $4.29.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in